Equillium, Inc.

NASDAQ: EQ · Healthcare · Biotechnology

PublicHQ La Jolla, CACIK 0001746466Reports USD

#459 of 1,394 Healthcare companies by revenue61st-percentile growth

EA Score

45D

FH 55DQ 28GM —SS 49

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$22.4M

Employees

Market cap

$103.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$41.1M$41.1M2024

Net income-$22.4M-$22.4M2025

Operating income-$23.6M-$23.6M2025

Total assets$31.9M$31.9M2025

Liabilities$3.3M$3.3M2025

Equity$28.6M$28.6M2025

Revenue trend

FY2022 – FY2024 · USD

$15.8M

FY22

$36.1M

FY23

$41.1M

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Equillium, Inc. booked $41.1M in FY2024 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -54.5% net margin.

Peers · Healthcare

Owlet, Inc.49D Solana Company49D Precision BioSciences, Inc.47D Atara Biotherapeutics, Inc.45D

Key facts

CEOBruce D. Steel

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Jolla, CA

ExchangeNASDAQ: EQ

Employees35

IPO date2018-10-12

Latest filings

8-K2026-05-29 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-15 10-K2026-03-25 8-K2026-03-25 8-K2026-03-13 10-Q2025-11-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.